Chemotherapy of seminoma in disseminated stages of satisfactory and intermediate prognosis


А. В. Сакало


To identify negative prognostic factors which influence survival in pts with disseminated seminoma in the favorable and intermediate prognostic group. Analyzed the results of treatment of the 27 patients with disseminated seminoma who had received chemotherapy at our department by modern chemotherapy regimen (EP ± bleomycin). With median follow-up 74 (3,5-96,9) months, 5-year OS rate was 85,2%. Only stage of the disease was identify as negative prognostic factors associated with progression and OS (р=0,05, р<0,0005). Prospective part of the study will include intensification of chemotherapeutical regiments by using 4PEB in pts with disseminated seminoma in intermediate prognostic group.


How to Cite
Сакало, А. В. (2016). Chemotherapy of seminoma in disseminated stages of satisfactory and intermediate prognosis. Health of Man, (1(56), 142–145.
Author Biography

А. В. Сакало, ДУ «Інститут урології НАМН України», м. Київ

A.V. Sakalo


International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Consensus Group // J Clin Oncol. 1997; 15: 594–603.

Fossa SD. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy / SD.F ossa, RTD.Oliver, SP.S tenning [et al.] // Eur J Cancer. 1997; 33: 1380–1387.

Bokemeyer C. Prognostic factors in patients with advanced metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a meta-analysis of prospective European trials / C. Bokemeyer, C. Kollmannsberger, A. Flechon [et al.] // Proc Am Soc Clin Oncol. 2002; 21: 186.

Tickoo SK. Testicular seminoma: a clinicopathologic and immunohisto-chemical study of 105 cases with specific reference to seminomas with atypical features / SK. Tickoo, B. Hutchinson, RJ. Motzer [et al.] // Int J Surg Pathol. 2002; 10.

Vuky J. Salvage chemotherapy for patients with advanced pure seminoma / J. Vuky, S. Tickoo, D. Bajorin [et al.] // J Clin Oncol. 2002; 20: 297–301.

Som Al. Recurrent seminomas: clinical features and biologic implications / Al. Som, R. Zhu, CC. Guo [et al.] // Urol Oncol. 2012 Jul-Aug; 30(4):494–501.

Gholam D. Advanced seminoma–treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease. A single-institution experience in 145 patients / D. Gholam, K. Fizazi [et al.] // Cancer. 2003; 98: 745–752.

Mencel P. Advanced seminoma: treatment results, survival and prognostic factors in 142 patients / P. Mence, R. Motzer [et al.] // J Clin Oncol. 1994; 12: 120–126.

Miller K. Salvage chemotherapy with vinblastine, ifosfamide and cisplatin in recurrent seminoma / K. Miller, P. Loehrer, L. Einhorn // J Clin Oncol. 1997; 15: 1427–1431.

Fedyanin M. Chemotherapy intensification in patients with advanced seminoma and adverse prognostic factors / M. Fedyanin, A. Tryakin, A. Bulanov [et al.] // J Cancer Res Clin Oncol. 2015 Jul; 141(7): 1259–64.

Fizazi K. A risk-adapted study of cisplatin and etoposide, with or without ifosfamide, in patients with metastatic seminoma: results of the GETUG S99 multicenter prospective study / K. Fizazi, R. Delva, A. Caty [et al.] // Eur Urol. 2014 Feb;65(2):381–6.